Avexa HIV drug success may make it a takeover target

03/19/2007 | Age (Melbourne, Australia), The

Analysts say the Australian biotech is a good bet to get U.S. FDA approval for its HIV drug apricitabine, which could place the firm in the sights of major drug companies. One analyst says the company could be a target for acquisition by GlaxoSmithKline or Gilead Sciences, which hold a large share of the HIV treatment market.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA